{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-315196","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.107873+00:00","generated_at":"2026-05-16T13:31:02.312750+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline","bullets":["Richard Fair appointed President, CEO and board member, effective December 11, 2025.","Co-founder Sam Kintz transitions to Head of Pipeline, remains at Enliven.","Fair receives $660,000 base salary, 55% target bonus, and option award for 875,000 shares.","Kintz receives $500,000 base salary, 55% bonus, and acceleration of 140,457 stock options.","Company plans to initiate Phase 3 trial for ELVN-001 in CML in 2026, citing need for commercialization expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-315196","json":"https://secwatch.observer/filing/0001193125-25-315196.json","markdown":"https://secwatch.observer/filing/0001193125-25-315196.md","text":"https://secwatch.observer/filing/0001193125-25-315196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525315196/0001193125-25-315196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525315196/d937094d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:31:02.312750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}